| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Natural Killer T-Cells | 22 | 2026 | 91 | 8.310 |
Why?
|
| Neuroblastoma | 25 | 2025 | 547 | 4.360 |
Why?
|
| Immunotherapy, Adoptive | 18 | 2026 | 950 | 2.720 |
Why?
|
| Cytotoxicity, Immunologic | 13 | 2026 | 271 | 1.800 |
Why?
|
| Interleukin-15 | 8 | 2026 | 104 | 1.620 |
Why?
|
| Lymphocyte Activation | 13 | 2024 | 630 | 1.410 |
Why?
|
| Antigens, CD1d | 9 | 2024 | 20 | 1.260 |
Why?
|
| Killer Cells, Natural | 9 | 2023 | 351 | 1.160 |
Why?
|
| Gangliosides | 5 | 2025 | 72 | 1.040 |
Why?
|
| Receptors, Antigen, T-Cell | 10 | 2023 | 498 | 0.960 |
Why?
|
| Neoplasms | 7 | 2025 | 2975 | 0.920 |
Why?
|
| Interleukin-18 | 1 | 2026 | 75 | 0.900 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2025 | 10 | 0.890 |
Why?
|
| Xenograft Model Antitumor Assays | 12 | 2026 | 1001 | 0.860 |
Why?
|
| Immunologic Memory | 1 | 2025 | 194 | 0.790 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2023 | 14 | 0.770 |
Why?
|
| Cancer Vaccines | 5 | 2019 | 188 | 0.750 |
Why?
|
| Mice | 33 | 2026 | 18161 | 0.730 |
Why?
|
| Immunotherapy | 5 | 2019 | 759 | 0.730 |
Why?
|
| Lymphoma, B-Cell | 3 | 2018 | 145 | 0.710 |
Why?
|
| Mice, SCID | 10 | 2023 | 583 | 0.700 |
Why?
|
| Cell Line, Tumor | 16 | 2026 | 3714 | 0.680 |
Why?
|
| Interleukins | 2 | 2020 | 121 | 0.670 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2023 | 636 | 0.660 |
Why?
|
| L-Selectin | 2 | 2018 | 18 | 0.620 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2016 | 194 | 0.620 |
Why?
|
| Galactosylceramides | 6 | 2018 | 15 | 0.610 |
Why?
|
| Mice, Inbred NOD | 9 | 2023 | 298 | 0.610 |
Why?
|
| Animals | 36 | 2026 | 33656 | 0.600 |
Why?
|
| Th1 Cells | 2 | 2018 | 158 | 0.580 |
Why?
|
| Receptors, Antigen | 2 | 2016 | 33 | 0.540 |
Why?
|
| Macrophages | 6 | 2024 | 660 | 0.540 |
Why?
|
| T-Lymphocytes | 10 | 2024 | 1707 | 0.530 |
Why?
|
| Glypicans | 3 | 2024 | 36 | 0.480 |
Why?
|
| Bone Neoplasms | 2 | 2020 | 470 | 0.470 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 1273 | 0.410 |
Why?
|
| Humans | 50 | 2026 | 130080 | 0.390 |
Why?
|
| Antigens, CD1 | 3 | 2003 | 23 | 0.380 |
Why?
|
| Tumor Microenvironment | 6 | 2025 | 707 | 0.370 |
Why?
|
| Medulloblastoma | 2 | 2013 | 376 | 0.360 |
Why?
|
| Cell Proliferation | 7 | 2020 | 2462 | 0.310 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2019 | 510 | 0.300 |
Why?
|
| Tumor Cells, Cultured | 7 | 2020 | 975 | 0.300 |
Why?
|
| Interleukin-2 | 2 | 2018 | 235 | 0.300 |
Why?
|
| Cells, Cultured | 7 | 2018 | 2885 | 0.290 |
Why?
|
| Antigen-Presenting Cells | 3 | 2019 | 123 | 0.280 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2007 | 236 | 0.280 |
Why?
|
| Oncogene Proteins | 2 | 2012 | 136 | 0.270 |
Why?
|
| Chemokine CCL2 | 2 | 2007 | 112 | 0.270 |
Why?
|
| Cytokines | 7 | 2016 | 1332 | 0.270 |
Why?
|
| STAT3 Transcription Factor | 5 | 2015 | 226 | 0.260 |
Why?
|
| Cell Movement | 3 | 2012 | 873 | 0.260 |
Why?
|
| Neoplasm Metastasis | 5 | 2015 | 713 | 0.240 |
Why?
|
| Flow Cytometry | 3 | 2010 | 765 | 0.240 |
Why?
|
| CD28 Antigens | 2 | 2016 | 76 | 0.220 |
Why?
|
| Apoptosis | 8 | 2020 | 1826 | 0.210 |
Why?
|
| Antigens, CD19 | 2 | 2023 | 189 | 0.210 |
Why?
|
| Neoplasm Transplantation | 4 | 2018 | 358 | 0.210 |
Why?
|
| Adjuvants, Immunologic | 3 | 2019 | 391 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 143 | 0.200 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2003 | 7 | 0.200 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 1 | 2023 | 14 | 0.190 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2023 | 33 | 0.190 |
Why?
|
| Etanercept | 1 | 2023 | 44 | 0.190 |
Why?
|
| Granzymes | 2 | 2018 | 44 | 0.190 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2019 | 688 | 0.190 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 19 | 0.180 |
Why?
|
| Macrophage-1 Antigen | 1 | 2002 | 21 | 0.180 |
Why?
|
| Nuclear Proteins | 2 | 2012 | 1208 | 0.180 |
Why?
|
| Protein Domains | 1 | 2023 | 252 | 0.180 |
Why?
|
| Interleukin-7 | 2 | 2017 | 46 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 815 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2004 | 500 | 0.180 |
Why?
|
| Receptors, IgG | 1 | 2002 | 59 | 0.180 |
Why?
|
| CRISPR-Cas Systems | 1 | 2025 | 316 | 0.180 |
Why?
|
| Interleukin-6 | 3 | 2024 | 410 | 0.170 |
Why?
|
| beta Catenin | 1 | 2023 | 197 | 0.170 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 201 | 0.170 |
Why?
|
| Monocytes | 1 | 2023 | 335 | 0.170 |
Why?
|
| Antibodies | 1 | 2002 | 316 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2018 | 57 | 0.160 |
Why?
|
| Vidarabine | 1 | 2020 | 91 | 0.160 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 781 | 0.160 |
Why?
|
| Homeostasis | 1 | 2004 | 712 | 0.160 |
Why?
|
| Carcinogenesis | 1 | 2023 | 336 | 0.160 |
Why?
|
| Neutrophils | 1 | 2002 | 362 | 0.160 |
Why?
|
| Transduction, Genetic | 3 | 2019 | 276 | 0.150 |
Why?
|
| Immunity | 1 | 2020 | 178 | 0.150 |
Why?
|
| CD3 Complex | 1 | 2019 | 95 | 0.150 |
Why?
|
| Antigens, Neoplasm | 3 | 2019 | 393 | 0.150 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 314 | 0.140 |
Why?
|
| Cyclophosphamide | 1 | 2020 | 426 | 0.140 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 55 | 0.140 |
Why?
|
| Hypoxia | 2 | 2016 | 247 | 0.140 |
Why?
|
| Bone Marrow | 3 | 2007 | 317 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2021 | 299 | 0.140 |
Why?
|
| Contrast Media | 1 | 2021 | 474 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2015 | 91 | 0.130 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 2 | 2015 | 10 | 0.130 |
Why?
|
| Child | 6 | 2023 | 26173 | 0.130 |
Why?
|
| Salmonella typhimurium | 2 | 2014 | 44 | 0.130 |
Why?
|
| Cell Survival | 2 | 2016 | 828 | 0.130 |
Why?
|
| Vaccines, Attenuated | 2 | 2014 | 174 | 0.130 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2016 | 25 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 977 | 0.120 |
Why?
|
| Melanoma | 2 | 2019 | 927 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2016 | 89 | 0.120 |
Why?
|
| Peptides | 1 | 2019 | 704 | 0.110 |
Why?
|
| Glycolysis | 1 | 2016 | 173 | 0.110 |
Why?
|
| Glioblastoma | 2 | 2017 | 372 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 2 | 2015 | 329 | 0.110 |
Why?
|
| N-Myc Proto-Oncogene Protein | 3 | 2013 | 57 | 0.110 |
Why?
|
| Glycolipids | 2 | 2019 | 33 | 0.110 |
Why?
|
| 4-1BB Ligand | 1 | 2014 | 11 | 0.110 |
Why?
|
| RNA, Messenger | 3 | 2013 | 2548 | 0.110 |
Why?
|
| Cell Line | 2 | 2014 | 2554 | 0.110 |
Why?
|
| Antineoplastic Agents | 2 | 2001 | 1800 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 2 | 2011 | 40 | 0.100 |
Why?
|
| Retroviridae | 1 | 2014 | 182 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2057 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 1 | 2014 | 716 | 0.090 |
Why?
|
| Glycosphingolipids | 1 | 2012 | 12 | 0.090 |
Why?
|
| Salmonella enterica | 1 | 2012 | 9 | 0.090 |
Why?
|
| Antigens | 1 | 2012 | 104 | 0.090 |
Why?
|
| Immunophenotyping | 2 | 2003 | 332 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2011 | 18 | 0.090 |
Why?
|
| Chemotaxis | 1 | 2011 | 59 | 0.080 |
Why?
|
| Melanoma, Experimental | 1 | 2011 | 39 | 0.080 |
Why?
|
| Drug Carriers | 1 | 2012 | 118 | 0.080 |
Why?
|
| Models, Immunological | 1 | 2010 | 35 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 975 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2017 | 4645 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 218 | 0.080 |
Why?
|
| Virulence Factors | 1 | 2012 | 180 | 0.080 |
Why?
|
| Salmonella | 1 | 2010 | 29 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 588 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 756 | 0.080 |
Why?
|
| Ceramides | 2 | 2000 | 47 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1366 | 0.070 |
Why?
|
| Vaccination | 2 | 2012 | 1051 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2011 | 662 | 0.070 |
Why?
|
| Graft vs Host Disease | 1 | 2014 | 688 | 0.070 |
Why?
|
| Ligands | 2 | 2019 | 480 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 246 | 0.070 |
Why?
|
| Male | 7 | 2024 | 64385 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 4691 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2016 | 3810 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2017 | 2008 | 0.070 |
Why?
|
| Female | 12 | 2024 | 70246 | 0.070 |
Why?
|
| Cerebellar Neoplasms | 1 | 2011 | 316 | 0.070 |
Why?
|
| Endothelial Cells | 1 | 2011 | 520 | 0.070 |
Why?
|
| Bone Marrow Cells | 1 | 2009 | 243 | 0.070 |
Why?
|
| CD56 Antigen | 2 | 2003 | 26 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2013 | 1265 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 992 | 0.060 |
Why?
|
| RNA Interference | 1 | 2007 | 491 | 0.060 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2025 | 68 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2024 | 14 | 0.050 |
Why?
|
| Cell Hypoxia | 2 | 2016 | 85 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 1205 | 0.050 |
Why?
|
| Thymus Gland | 1 | 2004 | 104 | 0.050 |
Why?
|
| Genes, myc | 1 | 2004 | 96 | 0.050 |
Why?
|
| RNA, Neoplasm | 1 | 2004 | 125 | 0.050 |
Why?
|
| Phenotype | 3 | 2013 | 4452 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 1208 | 0.050 |
Why?
|
| Child, Preschool | 4 | 2013 | 15005 | 0.050 |
Why?
|
| DNA Primers | 1 | 2004 | 600 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 17 | 0.050 |
Why?
|
| Perforin | 1 | 2003 | 24 | 0.050 |
Why?
|
| Protein Binding | 1 | 2007 | 1649 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2004 | 411 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2024 | 124 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 1319 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2002 | 542 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 2331 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2003 | 197 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 67 | 0.040 |
Why?
|
| Exocytosis | 1 | 2002 | 65 | 0.040 |
Why?
|
| Cytoplasmic Granules | 1 | 2002 | 50 | 0.040 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 19 | 0.040 |
Why?
|
| Immunomagnetic Separation | 1 | 2001 | 10 | 0.040 |
Why?
|
| U937 Cells | 1 | 2001 | 23 | 0.040 |
Why?
|
| HL-60 Cells | 1 | 2001 | 31 | 0.040 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2001 | 12 | 0.040 |
Why?
|
| Jurkat Cells | 1 | 2001 | 83 | 0.040 |
Why?
|
| Carcinoma, Small Cell | 1 | 2001 | 37 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 65 | 0.040 |
Why?
|
| Radiometry | 1 | 2021 | 49 | 0.040 |
Why?
|
| Brain Neoplasms | 3 | 2010 | 1305 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 406 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 1453 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 352 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2012 | 40 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 237 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 1278 | 0.040 |
Why?
|
| Receptors, Vitronectin | 1 | 2000 | 3 | 0.040 |
Why?
|
| Base Sequence | 1 | 2004 | 2729 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2011 | 154 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2001 | 689 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 83 | 0.040 |
Why?
|
| Fenretinide | 1 | 1999 | 9 | 0.040 |
Why?
|
| Integrins | 1 | 2000 | 89 | 0.040 |
Why?
|
| Transfection | 1 | 2001 | 961 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2015 | 1906 | 0.040 |
Why?
|
| Free Radical Scavengers | 1 | 1999 | 54 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2322 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 1363 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2019 | 13 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2000 | 105 | 0.040 |
Why?
|
| Infant | 3 | 2012 | 13269 | 0.040 |
Why?
|
| Adolescent | 3 | 2013 | 20801 | 0.040 |
Why?
|
| K562 Cells | 1 | 2019 | 97 | 0.040 |
Why?
|
| Adult | 4 | 2022 | 31011 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 61 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 1999 | 79 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 2 | 2012 | 979 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12821 | 0.040 |
Why?
|
| Retinoblastoma | 1 | 1999 | 86 | 0.040 |
Why?
|
| Chemokines | 1 | 2019 | 126 | 0.030 |
Why?
|
| Receptors, Cytokine | 1 | 2017 | 65 | 0.030 |
Why?
|
| Epitopes | 1 | 2019 | 323 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 380 | 0.030 |
Why?
|
| Genome, Human | 1 | 2004 | 1318 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2000 | 467 | 0.030 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2019 | 149 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2014 | 460 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1325 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 1999 | 521 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2003 | 1800 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2003 | 3349 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2016 | 117 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2016 | 155 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2010 | 435 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5034 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 699 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2013 | 719 | 0.020 |
Why?
|
| Side-Population Cells | 1 | 2013 | 13 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2001 | 1580 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 5167 | 0.020 |
Why?
|
| Receptor, trkB | 1 | 2012 | 22 | 0.020 |
Why?
|
| Th1-Th2 Balance | 1 | 2012 | 8 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2012 | 34 | 0.020 |
Why?
|
| Chemokine CCL20 | 1 | 2012 | 17 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2012 | 106 | 0.020 |
Why?
|
| Salmonella Vaccines | 1 | 2012 | 7 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 903 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2012 | 114 | 0.020 |
Why?
|
| Hemolysin Proteins | 1 | 2012 | 29 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2012 | 219 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 253 | 0.020 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 13 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2001 | 1547 | 0.020 |
Why?
|
| Codon | 1 | 2011 | 92 | 0.020 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 322 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2012 | 174 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2012 | 170 | 0.020 |
Why?
|
| Protein Transport | 1 | 2012 | 365 | 0.020 |
Why?
|
| Microfilament Proteins | 1 | 2012 | 269 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 324 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2012 | 409 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2012 | 419 | 0.020 |
Why?
|
| Salmonella Infections | 1 | 2010 | 30 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 902 | 0.020 |
Why?
|
| Virulence | 1 | 2010 | 268 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2013 | 598 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 62 | 0.020 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2009 | 22 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2014 | 947 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2012 | 695 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2011 | 892 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 262 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2009 | 316 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1588 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 126 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2013 | 883 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1097 | 0.010 |
Why?
|
| Disease Progression | 1 | 2012 | 2191 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 311 | 0.010 |
Why?
|
| Inflammation | 1 | 2012 | 1478 | 0.010 |
Why?
|
| Middle Aged | 1 | 2024 | 28314 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1931 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 17541 | 0.010 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2002 | 6 | 0.010 |
Why?
|
| Prognosis | 1 | 2012 | 4848 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 70 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2002 | 144 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2002 | 112 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2002 | 97 | 0.010 |
Why?
|
| Carbohydrate Sequence | 1 | 2001 | 19 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 2001 | 34 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2001 | 55 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 808 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2000 | 33 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2000 | 88 | 0.010 |
Why?
|
| Amino Acid Chloromethyl Ketones | 1 | 1999 | 10 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 1999 | 30 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 53 | 0.010 |
Why?
|
| Brain | 1 | 2011 | 3145 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 2002 | 8554 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 193 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2000 | 576 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1999 | 237 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1999 | 282 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 3464 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2000 | 1592 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2001 | 2076 | 0.010 |
Why?
|